Академический Документы
Профессиональный Документы
Культура Документы
9 May 2013 Thomas Krohn, RPh, MBA Eli Lilly and Company
Agenda
Case for change Disruption in motion Patient-Centric approach Changing our course
4/23/13
The Truly Staggering Cost Of Inventing New Drugs By Matthew Herber Forbes, February 2012
Drug Development
Innovation
Precompetitive
patent
Process
Competitive
$200 $100 $$300
Millions US$
4/23/13
Incremental Improvement
4/23/13
Disruptive Innovation
to S1'
Performance
to S2 S1
Disruptive Change
Time
Todays Model
Innovation
Precompetitive
Process patent
Competitive
Process patent
Competitive
Innovation
Precompetitive
Innovation
Process patent
Precompetitive Competitive
Innovation patent
Process
Precompetitive
Precompetitive
Competitive
Third Parties
4/23/13
11
Disruption in motion
Patient Communities
Patient-Driven Research
The Disruption
Motivation
Commons Licensing
Crowd
2. Consume 3. Curate
Uncurated Data
Curated Data
1. Collect
4. Connect
Public Data
Technology
ROAR
4/23/13
19
Crowd
2. Consume 3. Curate
Uncurated Data
Curated Data
1. Collect
4. Connect
Public Data
95,000,000
Pageviews/Month1
45,600,000
Patient driven pageviews/Month
What if.?
4/23/13 Eli Lilly and Company
Open
Patients
Platform
Follow us at www.lillycoi.com for updates on tool availability 4/23/13 Eli Lilly and Company 22
Patient-Centric Studies
1
Study Representation
PatientCentric Design
Design Challenge
Ct.Gov
Open
Study Design
Patients
Patient Voice
Platform
Clear eligibility Risk/Benefit My doctors role Study treatment Time to results Logistics
23
4/23/13
24
4/23/13
25
COI References
Website: www.lillycoi.com Whitepaper: link Public developer API: api.lillycoi.com Twitter: @Lilly_COI
4/23/13
27
Thanks
Thomas Krohn krohnta@lilly.com Eli Lilly and Company www.lillycoi.com 4/23/13 Eli Lilly and Company 28